Novo Nordisk Drug Fails Heart Trial

Novo Nordisk saw its stock fall. This happened after a new heart medicine did not work as hoped. The drug, named ziltivekimab, aimed to help patients with heart problems. It did not show a big enough benefit in its main study.

The company tested the drug on people with heart disease. These patients also had a kidney problem. Novo Nordisk wanted to see if ziltivekimab could stop serious heart events. These events include heart attacks and strokes. The drug did not reduce these events enough to be a success.

This news is a setback for Novo Nordisk. They are working on many new medicines. This trial was an important step for ziltivekimab. The company will now review the study results.

Investors watch these trials closely. A successful new drug can mean big growth for a company. When a drug fails, it can cause stock prices to drop. This shows how risky drug development can be.

Source: CNBC